Shanghai’s EpimAb Biotherapeutics filed US and China INDs simultaneously for a bispecific antibody that targets EGFR and cMET receptors. The company expects to test EMB01, its most advanced candidate, in patients with solid tumors. Founded three years ago, EpimAb uses its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) technology to generate bispecific molecules. It said EMB01 produced significant and long-lasting activity in several preclinical models of solid tumors.
Source: China Biotoday
